Several surrogate biomarkers including natriuretic peptide(NP), and growth differentiation factor-15(GDF-15) and ST2 has prognostic significance in heart failure(HF), and reductions in its value may predict clinical improvement. However, there are limited data regarding the prognostic value of these biomarkers during short-term follow-up after discharge in acute decompensated heart failure. The purpose of this study is to evaluate the prognostic value of short-term follow-up surrogate biomarkers for predicting prognosis of hospitalized patients with acute decompensated heart failure.
heart failure with reduced ejection fraction ( A 'reduced' ejection fraction (EF) defined as EF <40%): the presence of symptoms and/or signs of HF
heart failure with preserved ejection fraction ( A 'preserved' EF defined as EF≥ 40%) requires the all of the followings: a) the presence of symptoms and/or signs of HF b) elevated levels of natriuretic peptides (defined as B-type natriuretic peptide (BNP) >100pg/ml and/or N terminal B-type natriuretic peptide (NT-proBNP) >300pg/ml) c) any structural heart disease (left atrial volume index ≥ 34 mL/m2, left atrial dimension ≥ 50 mm, posterior or septal wall thickness ≥ 11mm)
any severe condition limiting life less than 3 months
the patient is not ready to contact by telephone at the end of the study
Hospitalized patients with acute decompensated heart failure
Cohort
Prospective
Not listed
The incidence rate (%) of composite endpoint including cardiovascular mortality or hospital readmission
Cardiovascular mortality: death due to heart failure aggravation, arrhythmia, cerebrovascular events, myocardial infarction. Hospital readmission: any readmission
The incidence rate (%) of all cause mortality
Any death after enrollment
The incidence rate (%) of cardiovascular mortality
Death due to heart failure aggravation, arrhythmia, cerebrovascular events, myocardial infarction.
The incidence rate (%) of hospital readmission
Any readmission after discharge
The incidence rate (%) of hospital readmission due to heart failure aggravation
Readmission due to heart failure aggravation after discharge
Click on the lead sponsor to view all of their trials.
Wonju Severance Christian Hospital
Lead sponsor
Roche diagnostics Korea
Collaborator
